View Article

Abstract

The Floating Drug Delivery System (FDDS) represent a new generation of gastro-retentive drug delivery systems, which are aimed at increasing the gastro residence time and increasing the bioavailability of drug with narrow absorption windows, low solubility, or site-specific activity of the upper gastrointestinal tract. Traditional delivery methods of oral dosages are generally characterized by high rates of gastric emptying, resulting in incomplete drug absorption and variable plasma drug levels. The way to address these shortcomings is by creating FDDS that can be kept afloat in gastric fluids to facilitate sustained and controlled drug delivery. Natural mucilage is a new material that is showing promise as a substitute of synthetic polymers in FDDS because of its biocompatibility, biodegradability, non-toxicity and cost-effectiveness. Mucilage is the by-product of vegetable products like fenugreek, okra and flax seed which have been reported to have high levels of swelling, forming gel and increasing viscosity properties and are thus very helpful in floating preparations. This review comprehensively discusses the formulation strategies of mucilage-based FDDS including effervescent and non-effervescent systems and their mechanism of action, including buoyancy, density reduction and polymer swelling. In addition, another valuable point to be mentioned is that physicochemical properties of natural mucilage, such as swelling index, viscosity, and biodegradability are also of paramount importance when their usage in drug delivery control and gastric retention is concerned. The review also highlights the applications that are present, advantages over synthetic polymers and new technologies in the field. Despite some of the limitations such as lack of uniformity of the natural sources and standardization, the mucilage-based FDDS can hold a massive potential of developing safe, effective and sustainable delivery system.

Keywords

Floating Drug Delivery system, Natural mucilage, Gastro retentive systems, Swelling polymers, Controlled drug release, Buoyancy mechanism, Bioavailability

Introduction

GRDDS constitute an emerging technology in oral drug delivery that seeks to improve the residence time of oral dosage forms in the stomach and augment bioavailability of drugs and their therapeutic action. They are particularly effective when the absorption time of the drug in the upper gastrointestinal tract is short, it is insoluble at alkaline pH or acts locally in the stomach.[1] One of the GRDDS technologies which has attracted a lot of interest is floating drug delivery systems (FDDS) because of their potential to stay afloat on gastric fluids, thereby increasing the gastric retention time without disrupting normal gastric emptying. FDDS work through their low density relative to gastric contents to enable them to float to the surface releasing the drug in a controlled way.[2] The necessity of floating systems can be explained by the fact that traditional oral drug forms have several shortcomings, including unpredictable emptying of the stomach, which results in low absorption of drugs and variable plasma drug levels. FDDS overcome these issues by enhancing the solubility of drugs, reducing drug waste, and producing a prolonged release of drugs in the stomach. [3]

Traditionally, synthetic polymers such as hydroxypropyl methylcellulose (HPMC) and carbopol have been widely used in FDDS formulations. Nevertheless, these types of polymers have a number of drawbacks, such as the possibility of toxicity, high price, environmental impact, and non-biodegradability. Other problems like irritation caused by polymer and regulatory limitations have also prompted the search of less toxic options. [4] Natural mucilage is a promising alternative in recent years because of its biocompatibility, biodegradability, non-toxicity, and cost-effectiveness. Mucilage is a polysaccharide that is extracted by plants (seeds, leaves, and roots) and has excellent swelling, gel-forming, and drug-releasing characteristics, thus highly applicable in floating drug delivery. [5] Moreover, natural mucilage-based systems are eco-friendly, provide patients with compliance, and enhance therapeutic performance, which has been attracting more and more research in pharmaceuticals. Such materials would serve as an efficient matrix forming agent, binders, and release retardants and help to develop effective floating drug delivery systems. [6]

2. Overview of Floating Drug Delivery Systems

2.1 Definition and Concept

Floating Drug Delivery Systems (FDDS) is a gastro-retentive system, a system that assists in increasing the gastrointestinal retention of dosage in the gastric fluids. They also have lower bulk density than gastric contents (average of 1.004 g/cm 3) and therefore are able to ascend to the surface of the stomach without being forced out of the pylorus. [7].The basic principle of FDDS lies in the possibility of attaining the controlled release and the sustained release of drugs and the dose form is located in the stomach.[8] The system is then either made to give out gas, or it swells to reduce the density to allow the system to be retained suspended and then the drug to be introduced at a regulated rate after administration. [8]   After administration, the system is either made to produce gas or it swells to decrease the density so that it can be kept suspended and the drug could be delivered at a controlled rate. This is particularly applicable in drugs that have a site-specific absorption in the upper gastrointestinal tract or labile in the presence of the intestinal conditions. [9].

2.2 Advantage and Limitations

Advantages

Floating Drug Delivery Systems have a number of therapeutic and formulation benefits:

  • Increased gastric retention time and subsequent rise in drug bioavailability [10].
  • Constant and slow drug release, decreasing dosing rate.
  • Enhanced absorption of drugs having narrow absorption indices.
  • Localized effect of drugs in the stomach, useful in gastric disorder.
  • Less fluctuation in plasma concentration, enhancing patient compliance.
  • Reduced wastage of drugs, particularly those that are not well soluble.

Limitations

In spite of their benefits, FDDS have some limitations as well:

  • Reliance on the amount of gastric fluid, which can be different in patients.
  • Inappropriateness to drugs that result in gastric irritation.
  • Variability in gastric emptying time, affecting system performance
  • Not suitable in drugs that are very soluble in acidic pH.
  • Problems with providing consistent buoyancy to all recipes.
  • There is the possibility of dumping the dose in the case of a system failure [11].

2.3 Classification of Floating Drug Delivery Systems

It is generally grouped into effervescent and non-effervescent systems, depending on how they reach their goal of buoyancy.

2.3.1 Effervescent Systems

Effusive systems are based on the production of gases (typically CO 2) in the effort to create buoyancy. The gas generating agents often include Sodium Bicarbonate, citric acid or tartaric acid and are commonly found in some system.

Mechanism:

  • When it comes into contact with gastric fluid it reacts with an acid-base reaction.
  • CO2 is generated and gets trapped within the polymer matrix
  • The System is made less dense and comes to rest.

Types:

  • Gas-generating tablets
  • Volatile liquid-containing systems

Critical aspect

  • Short floating lag time (rapid floating initiation)
  • Appropriate in sustained release preparations.

Systems of the effervescent type are highly utilized as they are simple and effective to gain an immediate buoyancy [12].

2.3.2 Non-Effervescent Systems

Non-effervescent systems have no dependence on the generation of gases; they make use of swelling and geling polymers to ensure buoyancy.

 Mechanism:

•      Gastric fluid is absorbed by hydrophilic polymers.

•      There is swelling, and a gel barrier is created.

•      The system becomes lower in density and floats.

Types:

Hydrodynamically balanced systems (HBS).

•      Swelling systems

Floating beads and microspheres.

•      Alginate-based systems

Critical aspect:

  • Longer floating duration
  • Stabilized and predictable performance.
  • Superset in natural mucilage preparations.

They are especially beneficial when natural polymers like mucilage are used because they are good in swelling and forming matrices [13].

Mechanism of Floating Systems.

3.1 Buoyancy Principle

The basic principle underlying Floating Drug  Delivery  System (FDDS) is the law of buoyancy where the dosage form floats on gastrointestinal fluid, because it is less dense than the stomach contents. Archimedes principle states that the upward forces of buoyancy of a body immersed in a fluid is equal to the weight of the fluid that it displaces. In the case where the upward force is greater than the force of gravity on the dosage form, it floats [14].

Polymers and gas-generating agents are added to FDDS to make sure that dosage form buoyed over a period of time. This increases the gastric absorption of drugs and boosts bioavailability, particularly in drugs having narrow absorption window [15].

3.2 Density Reduction

One of the key factors to floatation is density reduction. The density of the system should be less than that of the stomach fluid (~1.004g/cm3). This is possible in various mechanisms in accordance to the type of formulation:

•           Effusive systems: A carbon dioxide gas is produced through acid-base reactions (e.g., Sodium Bicarbonate and Citric acid), and traps within the polymer matrix, reducing density.

•           Non-effervescent systems: Swelling polymers are used, which increase in volume but not mass due to being moistened.

This increases the density so that the dosage form can be floated and remain in the stomach during prolonged durations of time [16]. Additionally, there should be ideal density/structural integrity ratio to prevent premature sinking or breaking. [17].

3.3 Swelling and Gel Formation

Gel formation and swelling are key factors in non-effervescent floating systems. The polymers, including natural mucilage, are hydrophilic and absorb the gastric fluid and hydrate rapidly, which results in:

  • Swelling of the polymer matrix
  • Development of a gel barrier of a viscous gel.
  • Cavities filled by air in the matrix.

Such a swollen gel structure does not only help in the buoyancy but also regulates drug release by providing a diffusion barrier. Floating behavior and the rate of drug release depend on the rate of swelling and gel strength [18].

The natural mucilage is especially beneficial in this mechanism because it has a high water-binding capacity and a strong gel-forming ability, thus being suitable in sustained-release floating formulations [19].

 

 

 

Figure 1: Mechanism of floating drug delivery system

 

 

 

 

 

 

Figure 2: Classification of Floating Drug Delivery Systems

 

 

 

Figure 3: A Schematic Representation of Buoyancy Mechanism.

 

4. Natural Mucilage: Sources and Properties.

4.1 Definition of Mucilage

Mucilage is a designation of a group of natural, high-molecular-weight polysaccharides, obtained mostly by means of plants, that are solutions that are viscous and gel-like when wet. They are normally made up of complex carbohydrates that include arabinose, galactose, rhamnose and uronic acids, which make them very good in water binding and swelling [20].

Mucilage is a very popular polymer in the manufacturing pharmaceutical industry as a binder, thickening agent, stabilizer, and controlled-release polymer, especially in gastroretentive drug delivery systems because it is biocompatible, non-toxic and eco-friendly [21].

4.2 Sources of Natural Mucilage.

Natural mucilage is mostly obtained of vegetable origin, particularly seeds, leaves, roots, and bark. These are renewable, cheap, and are common materials that make them appealing as an alternative to synthetic excipients.

Plant-Based Sources

Fenugreek

  • Scientific name: Trigonella foenum-graecum.
  • Aggalactomannan polysaccharides-rich.
  • Both exhibited a high swelling index and viscosity.
  • Most commonly used in sustained release preparations.

 Okra

  • Scientific name: Abelmoschus esculentus.
  • Contains acidic polysaccharides
  • Good film-forming and binding properties.
  • Floating and matrix tablet compatible.

 Flaxseed

  • Scientific name: Linum usitatissimum.
  • Neutral and acidic polysaccharides.
  • Good water retention and gel-forming properties.
  • Application in controlled-release systems.

Increasingly, these mucilages produced by plants are used in floating drug delivery system due to their natural source, safety, and multifunctional characteristics [22].

4.3 Physicochemical Characteristics of Mucilage.

Mucilage physicochemical properties control its performance in floating drug delivery systems:

4.3.1 Swelling Index

Swelling index is a scale of the ability of mucilage to take in water and swell. When mucilage comes in interaction with stomach fluid it hydrates and swells to form a gel-like matrix that contributes to:

•           Decrease in system density.

•           Enhanced buoyancy

•           Controlled drug release

The desirable swelling index is high to increase the duration of gastric retention and continuous drug delivery [23].

 4.3.2 Viscosity

Viscosity is an indicator of thickness and resistance to flow of mucilage solutions. It is important in:

•           Creation of a powerful gel shield.

•           Drug diffusion control

•           Stability of the dosage form

Higher viscosity mucilage is also more effective at release retardation and matrix integrity, and therefore is appropriate in floating formulations [24].

4.3.3 Biodegradability

Natural mucilage is biodegradable by nature, meaning that it can be decomposed by the biological process into non-toxic residues.. This property ensures:

  • Minimal toxicity and safety.
  • Environmental sustainability
  • Biocompatibility.

Biodegradability is a significant advantage over synthetic polymers, particularly in the development of environmentally benign pharmaceutical preparations. [25].

 

Table 1: Sources of Natural Mucilage and Their Biological Origin

S. No.

Source (Common Name)

Scientific Name

Biological Origin (Part Used)

Major Constituents

Key Properties

Reference

1

Fenugreek

Trigonella foenum-graecum

Seeds

Galactomannan

High swelling, viscosity

[64]

2

Okra

Abelmoschus esculentus

Fruits (pods)

Acidic polysaccharides

Film-forming, thickening

[65]

3

Flaxseed

Linum usitatissimum

Seeds

Arabinoxylans, rhamnogalacturonan

Gel-forming, water retention

[66]

4

Psyllium

Plantago ovata

Husk (seed coat)

Arabinoxylans

High swelling, laxative effect

[65]

5

Tamarind

Tamarindus indica

Seeds

Xyloglucan

Gel-forming, stabilizing

[66]

6

Hibiscus

Hibiscus rosa-sinensis

Leaves/Flowers

Mucilaginous polysaccharides

Thickening, bioadhesive

[67]

7

Aloe vera

Aloe barbadensis

Leaves (gel)

Glucomannan

Soothing, gel-forming

[68]

8

Neem

Azadirachta indica

Bark/Leaves

Polysaccharides

Binding, antimicrobial

[69]

9

Guar gum

Cyamopsis tetragonoloba

Seeds

Galactomannan

Thickening, stabilizing

[70]

10

Cassia tora

Cassia tora

Seeds

Galactomannan

Swelling, binder

[71]

 

Table 2: Physicochemical Properties of Natural Mucilage Used in FDDS

S. No.

Mucilage Source

Swelling Index

Viscosity Behavior

Biodegradability

Functional Role in FDDS

Reference

1

Fenugreek (Trigonella foenum-graecum)

High

High viscosity (gel-forming)

Biodegradable

Matrix former, sustained release

[72]

2

Okra (Abelmoschus esculentus)

Moderate–High

Pseudoplastic

Biodegradable

Binder, release retardant

[73]

3

Flaxseed (Linum usitatissimum)

High

High viscosity, shear-thinning

Biodegradable

Gel-forming agent, controlled release

[74]

4

Psyllium (Plantago ovata)

Very High

Highly viscous

Biodegradable

Swelling agent, buoyancy enhancer

[75]

5

Tamarind (Tamarindus indica)

Moderate

Moderate viscosity

Biodegradable

Stabilizer, matrix former

[76]

6

Aloe vera (Aloe barbadensis)

Moderate

Gel-like consistency

Biodegradable

Release modifier, gel base

[77]

7

Guar gum (Cyamopsis tetragonoloba)

High

Very high viscosity

Biodegradable

Thickening agent, sustained release

[77]

8

Cassia tora (Cassia tora)

Moderate–High

Moderate viscosity

Biodegradable

Binder, swelling agent

[78]

9

Hibiscus (Hibiscus rosa-sinensis)

Moderate

Moderate viscosity

Biodegradable

Bioadhesive, thickener

[79]

 

10

Xanthan gum (microbial origin)

High

Highly viscous, shear-thinning

Biodegradable

Stabilizer, controlled release

[80]

 

5. Extraction and Purification of Mucilage

5.1 General Extraction Process

Natural mucilage extraction of plants is a series of standardized operations aimed at extracting water soluble polysaccharides, with minimum contaminants. It is typically triggered by plant material (seeds, leaves or bark) cleaning and drying, and a reduction in size to expand surface area to be extracted. The fine material is impregnated or sprayed in distilled water, then the fine material is stirred or heated mechanically to stimulate the release of mucilage to the water medium [26].The wet extract is filtered with muslin cloth or centrifuged in order to isolate the insoluble residues, to obtain a crude mucilage solution. Organic solvents such as ethanol, acetone or isopropyl alcohol are then added to the solution to be precipitated in an approximately 1:2 or 1:3 mixture to isolate mucilage and soluble impurities. The precipitated mucilage is gathered, washed and dried in controlled conditions (40 50 C) and then milled and sieved to become a fine powder which can be taken in pharmaceutical preparations. [27].

5.2 Purification Techniques

To purify mucilage, it needs to be removed to remove potential contaminants (proteins, pigments and inorganic materials) that may affect its functionality and stability. A number of techniques are used:

  • Solvent precipitation: This is a technique that is usually used as the first step in purification, and the solution is dissolved in alcohols [28].
  • Centrifugation: Suspended impurities are eliminated and Clarity of the mucilage suspension enhanced.
  • Dialysis: Eliminates low molecular weight impurities such as salts and sugars
  • Enzymatic treatment: The unwanted biomolecules are degraded by the use of proteins or amylases.
  • Activated charcoal treatment: Removal of pigments, increases intensity of color and purity.

Developed purification procedures, including ultrafiltration and chromatography procedures are also used to achieve highly purified mucilage to be used in special pharmaceutical purposes [29].

5.3 Effects of Factors on Yield of Mucilage.

The quality and quantity of extracted mucilage will depend on the different physicochemical and process-related parameters:

  1. The type of the plant material is: oak bark.
  • Type, maturity and storage of the source of the plants - The conditions have a great impact on the yield.
  • Seed Generally, the mucilage content of seeds is higher as compared to leaves or bark.
  1. Extraction Medium
  • pH and type of solvent affect solubility and extraction efficiency
  • Water is ideal, but acidic or alkaline soils can increase yield.
  1. Temperature
  • Mid temperature heating enhances extraction.
  • Excess heat: This can destroy polysaccharides.
  1. Extraction Time
  • Soaking time adequately enhances mucilage release.
  • Prolonged extraction may lead to degradation
  1. Precipitation Solvent Ratio.
  • High solvent ratios increase recovery but can impact on purity.
  1. Drying Conditions
  • Functional properties are maintained with controlled drying.
  • High temperatures could decrease the ability to swell and viscosity.

These factors are essential to optimize to achieve maximum yield, purity, and functionality of mucilage in FDDS [30].

 

 

 

Figure 4: Flowchart of Mucilage Extraction and Purification Process

 

6. Use of Natural Mucilage in FDDS.

The natural mucilage plays a very significant multipurpose role in FDDS, due to its unusual physicochemical properties of hydration capacity, gel formation and biocompatibility. These characteristics enable mucilage to be an effective polymer in controlling the properties of buoyancy and drug release.

6.1 Swelling Behaviour

One of the most effective function of natural mucilage in FDDS is swelling. When mucilage comes in interaction with stomach fluid, it absorbs water quickly and volumetric expansion occurs. This swelling causes:

  • Reduction in density of the dosage form
  • Enhanced buoyancy
  • Extended gastric retention time.

The swelling phenomenon varies with the polymer structure, level of hydration and the environmental pH. Very swellable mucilage creates a moist outer layer that enables the system to stay afloat over long durations [31]. Also, swelling is involved in the establishment of a diffusion barrier that controls the release of drugs [32].

6.2 Gel Formation

The presence of hydrophilic polysaccharides makes natural mucilage have an excellent gel-forming ability. When hydrated, such polymers create a sticky and adhesive gel layer surrounding the dosage form.

This gel layer has a variety of purposes:

•           Functions as a shield against erosion.

•           Ensures the structural soundness of the formulation.

•           Gastric penetration of the fluid.

The gel layer strength and consistency have a profound effect on floating behavior and kinetics of drug release. A firmer gel guarantees longer retention and extended release [33].

6.3 Matrix Formation

Mucilage is a matrix-forming agent in floating systems, as it creates a three-dimensional network surrounding the drug. This matrix:

  • Gives mechanical strength to the dosage form.
  • Stops the breakdown of gastric fluid.
  • Regulates diffusion routes of drugs.

The matrix system enables the drug to be uniformly distributed and gives a consistent release profile. Mats based on natural mucilage are especially beneficial, as they are biodegradable and non-toxic [34].

6.4 Drug Release Retardation

The retarded release of drugs is one of the most important functions of mucilage in FDDS, as it allows the drug to have prolonged therapeutic effect. This is achieved through:

  • Formation of a gel barrier slowing diffusion of drugs.
  • Higher viscosity, impeding the movement of drugs.
  • Regulated dissolution of the polymer structure.

The release of drugs through mucilage-based systems typically goes through either diffusion-controlled or anomalous transport. Polymer concentration, viscosity, and cross-linking degree can be adjusted to control the release rate [35].

Natural mucilage is particularly effective in the maintenance of drug delivery because of their high water retention and gel stability, which is suitable with once-daily formulation.

 

 

S. No.

Functional Role

Mechanism of Action

Impact on FDDS Performance

Example Mucilage

Reference

1

Swelling Agent

Absorbs gastric fluid and expands to increase volume

Reduces density and enhances buoyancy

Fenugreek, Psyllium

 [81]

2

Gel-Forming Agent

Forms viscous gel layer upon hydration

Maintains floatation and controls drug diffusion

Okra, Aloe-Vera

[82]

3

Matrix Former

Creates a three-dimensional polymer network

Provides structural integrity and sustained release

Guar gum, Tamarind

 [83]

4

Drug Release Retardant

Forms diffusion barrier and controls erosion

Prolongs drug release and improves bioavailability

Flaxseed, Cassia tora

 [84]

5

Binder

Enhances inter-particle adhesion during compression

Improves tablet hardness and stability

Hibiscus, Neem

[85]

6

Bio-adhesive Agent

Interacts with gastric mucosa via hydrogen bonding

Increases gastric residence time

Okra, Psyllium

[86]

7

Stabilizer

Maintains uniform dispersion of drug and excipients

Prevents phase separation and improves consistency

Guar gum, Xanthan gum

[87]

8

Thickening Agent

Increases viscosity of formulation

Enhances gel strength and controls release rate

Aloe vera, Fenugreek

 [88]

9

Floating Enhancer

Entraps air and reduces system density

Improves floating lag time and duration

Psyllium, Guar gum

 [89]

10

Release Modifier

Modulates diffusion and erosion rates

Achieves controlled and sustained drug delivery

Tamarind, Flaxseed

 [90]

 

7. Floating Drug Delivery System Strategies of Formulation.

The choice of approaches to formulate floating drug delivery systems (FDDS) can vary with the dosage form, drug properties, and desired release profile. Of these, floating tablets, beads, microspheres and gels have been extensively investigated because they are effective in improving gastric retention and controlled drug delivery.

7.1 Floating Tablets

The most widely used FDDS is floating tablets as it is simple and easy to produce. Such systems are typically ready-to-wear by direct compression or wet granulation methods involving use of hydrophilic polymers and gas generating substances.

 Mechanism:

  • CO 2 is formed by effusive agents (e.g., Sodium Bicarbonate)
  • Gas gets enclosed in the hydrated polymer matrix
  • Tablet density decreases → floats on gastric fluid

 Advantages:

  • Single formulation and easy scalability.
  • Suitable to sustained-release drugs.
  • Good patient compliance

Natural mucilage floating tablets have improved swelling and gelation, enhancing buoyancy and control of drug release [36].

7.2 Floating Beads

Multi-particulate systems of floating beads are usually prepared by ionotropic gelation methods. Beads can be produced by dropping natural polymers (e.g., alginate, mucilage) into cross-linking solutions (e.g., calcium chloride).

 Mechanism:

  • Porous, low-density, beads formed.
  • Trapping of air or gas in the matrix.
  • Beads are suspended and give out drug slowly.

 Advantages:

  • Even distribution of the stomach.
  • Less chance of dose dumping.
  • Increased control of drug release.

The efficacy of floating beads that have been prepared with natural mucilage in the context of better buoyancy and encapsulation is evidenced [37].

7.3 Floating Microspheres

Floating microspheres (synonymous with hollow microspheres or microballoons) are low-density, hollow, round particles formed by packaging a gas or liquid inside, and are expected to be buoyed temporarily over extended times.

 Preparation Techniques:

  • Solvent evaporation
  • Emulsion solvent diffusion
  • Spray drying

 Mechanism:

  • Formation of hollow internal structure
  • Lower density allows floatation.
  • Drug diffused and eroded through polymer.

 Advantages:

  • Long gastric residence time.
  • Regulated and predictable release of drugs.
  • Enhanced bioavailability

Microspheres made of natural mucilage offer good biocompatibility and prolonged release properties [38].

7.4 Floating Gels

Floating gels are in situ gelling systems, which change to sol-to-gel in the stomach. These systems are specifically applicable when it comes to liquid formulations.

 Mechanism:

  • Liquid formulation is changed to a gel when it is in contact with gastric pH or ions.
  • Floating is possible through generation of gases or polymer swelling.
  • Drug release is controlled by gel matrix.

 Advantages:

  • Appropriate to use in children and elderly.
  • Easy administration
  • Uniform drug distribution

Gels made of natural mucilage have high gelation and viscosity and are a good choice in gastro-retentive applications [39].

 

 

 

Figure 5: Different Formulation Approaches of Floating Systems

 

Table 4: Formulation Techniques and Their Characteristics

S. No.

Formulation Technique

Method Description

Dosage Form Produced

Key Characteristics

Advantages

Limitations

Reference

1

Direct Compression

Powder drug + polymer compressed directly into tablets

Floating tablets

Simple process, uniform mixing

Cost-effective, scalable

Limited for poorly compressible drugs

[91]

2

Wet Granulation

Drug granulated with binder solution before compression

Floating tablets

Improved flow and compressibility

Suitable for high-dose drugs

Time-consuming, moisture sensitive

[92]

3

Effervescent Technique

Incorporation of gas-generating agents (e.g., NaHCO?)

Floating tablets/capsules

Rapid CO? generation

Quick buoyancy, easy design

Stability issues due to moisture

[93]

4

Ionotropic Gelation

Polymer dropped into cross-linking solution (Ca²?)

Floating beads

Formation of gel beads

Mild process, good encapsulation

Variable bead size

[94]

5

Solvent Evaporation

Drug-polymer solution emulsified, solvent evaporated

Microspheres

Hollow/porous structure

Controlled release, buoyant particles

Use of organic solvents

[95]

6

Emulsion Solvent Diffusion

Internal phase diffuses into external phase forming particles

Microspheres

Uniform particle size

High drug entrapment

Process complexity

[96]

7

Spray Drying

Atomization of drug-polymer solution into hot air

Microspheres/powder

Rapid drying, fine particles

Scalable, uniform size

Thermal degradation risk

[97]

8

In situ Gelation

Liquid formulation gels in gastric environment

Floating gels

Sol-to-gel transition

Easy administration, uniform distribution

Stability challenges

[98]

9

Freeze Drying (Lyophilization)

Removal of solvent by sublimation

Porous floating systems

Highly porous structure

Enhanced buoyancy

Costly process

[99]

10

Melt Granulation

Drug mixed with meltable binder

Floating tablets/granules

Solvent-free process

Environment-friendly

Limited polymer selection

[100]

 

8. Floating Drug Delivery Systems-Evaluation Parameters.

The analysis of Floating Drug Delivery systems (FDDS) is vital in determining the flow characteristics, floating behavior, and controlled drug release characteristics. These parameters are categorically divided into pre-compression and post-compression studies.

8.1 Pre-compression Parameters

Investigations Before the formulation of the tablets, pre-compression studies are conducted to determine the flow ability and compressibility of the blended powder.

 8.1.1 Bulk Density

The ratio of the mass of powder to the bulk volume including the spaces between particles is known as bulk density.

Significance:

  • Shows the packing capacity of powder.
  • Affects uniformity of weight of tablets.
  • Affects compressibility

Reduced bulk density is beneficial to floating systems because it helps decrease the overall density of the dosage form [40].

 8.1.2 Angle of Repose

Angle of  repose is an assess of flowability  the powder that is the maximum angle of a pile of powder between the upper surface of the pile and the horizontal plane.

Significance:

  • Denotes flow habits of powder.
  • Helps in predicting uniform die filling

A value that is lower than 30 degrees in angle of repose implies good flow properties, which is a requirement to make uniform pill formulations [41].

8.2 Post-compression Parameters

The post-compression tests measure of the final dose form, particularly its floating capability and drug release properties.

 8.2.1 Floating lag time (FLT)

Floating lag time is the time of occurrence of the dosage form to ascend to the top of the gastric fluid following the administration.

Significance:

  • Suggests efficiency of buoyancy.
  • Short FLT (less than 1 min) is good.

FLT is based on the production of gases, the hydration of polymers, and the density of pills [42].

 8.2.2 Total Floating Time (TFT)

Total Floating Time is the time that the dosage form will stay on the surface of the gastric fluid.

Significance:

  • Gastric retention ability.
  • Longer TFT guarantees a longer drug release.

The optimal FDDS must be able to stay buoyant over a minimum of 12 hours to promote a lasting therapeutic effect [43].

 8.2.3 Drug Release Profile

Drug release profile are done to determine the rate and extent of drug kinetics of the floating system with time.

Methods:

  • Dissolution testing with USP equipment.
  • Regular sampling.

Kinetic Models:

  • Korsmeyer-peppas model
  • First order release
  • Zero order
  • Higuchi model

The release profile aids in identifying whether the formulation results in controlled or sustained drug delivery. The formation of gel barriers in natural mucilage-based systems tends to cause diffusion-controlled release [44].

 

Table 5: Evaluation Parameters for Floating Drug Delivery Systems

 

S. No.

Parameter

Category

Method / Equation

Significance

Acceptance Criteria / Observation

Reference

1

Bulk Density

Pre-compression

Mass / Bulk volume

Determines packing ability

Lower density preferred for buoyancy

[101]

2

Tapped Density

Pre-compression

Mass / Tapped volume

Indicates compressibility

Used to calculate Carr’s index

[102]

3

Angle of Repose

Pre-compression

tan θ = h/r

Evaluates flow properties

< 30° = good flow

[103]

4

Carr’s Index

Pre-compression

[(Tapped – Bulk)/Tapped] ×100

Compressibility index

5–15% = excellent flow

[104]

5

Hausner Ratio

Pre-compression

Tapped / Bulk density

Flowability indicator

< 1.25 = good flow

[105]

6

Floating Lag Time (FLT)

Post-compression

Time to float in 0.1N HCl

Indicates buoyancy onset

< 60 seconds desirable

[106]

7

Total Floating Time (TFT)

Post-compression

Duration of floatation

Measures gastric retention

> 12 hours preferred

[107]

8

Tablet Hardness

Post-compression

Monsanto / Pfizer tester

Mechanical strength

4–8 kg/cm²

[108]

9

Friability

Post-compression

Roche friabilator

Tablet durability

< 1% weight loss

[109]

10

Drug Release Profile

Post-compression

Dissolution study (USP apparatus)

Evaluates release kinetics

Sustained/controlled release pattern

[110]

 

9. Uses of Floating Drug Delivery Systems.

The floating drug delivery system (FDDS) has become of significant significance in pharmaceutical studies because of their capability to rise the gastric residence time as well as enchance the efficacy of the drugs. They are especially applicable with drugs that need site-specific absorption, location gastric effect, or a greater bioavailability.

9.1. Drugs with Narrow Absorption Window.

Drugs have a narrow absorption window (NAW), which implies that they are mainly absorbed in the upper section of the gastrointestinal tract like the stomach or proximal small intestine. Traditional dosage forms do not have enough residence time in this region, and thus, the drug is not absorbed completely.

FDDS can address this shortcoming by holding the dosage form in the stomach longer, and in the process ensuring that the drug can be released at its optimum absorption point. This leads to:

  • Enhanced drug absorption
  • Reduced dosing frequency
  • Improved therapeutic efficacy

Such drugs are levodopa, riboflavin and furosemide. The floating systems are a major way of enhancing their bioavailability by avoiding premature passages to the lower gastrointestinal tract (Huang et al., 2022)[45].

9.2 Local Stomach Action

FDDS are most useful with drug that are meant to have local therapeutic effect in the stomach, e.g., in the treatment of gastric ulcers, gastritis and infections with Helicobacter pylori.

FDDS allow the drug to have a long-term contact with the gastric mucosa resulting in:

  • Increased local drug concentration.
  • Improved therapeutic outcomes
  • Less side effects in the system.

As an illustration, antibiotics and antacids that are a floating system exhibit a greater efficacy against gastric infections because of a longer residence time [46].

9.3 Improved Bioavailability

Another most notable use of FDDS is in increasing bioavailability, especially of drugs that exhibit:

  • Poorly soluble at intestinal pH.
  • Unstable in alkaline environments.
  • Extensive first-pass metabolism

FDDS offer a controlled release environment, which enhances the absorption and dissolution of drugs by keeping the drug in the stomach. This results in:

  • Raised plasma concentration of drug.
  • Less variable absorption of drugs.
  • Improved therapeutic efficiency

FDDS based on natural mucilage are particularly beneficial because of their ability to swell and form a gel that additionally improves the control of drug release and bioavailability [47].

 

Table 6: Applications of Mucilage-Based Floating Systems with Example Drugs

S. No.

Application Area

Example Drug

Therapeutic Use

Role of Mucilage in FDDS

Outcome / Benefit

Reference

1

Narrow Absorption Window

Levodopa

Parkinson’s disease

Sustains release in stomach

Improved absorption

[111]

2

Narrow Absorption Window

Riboflavin

Vitamin deficiency

Prolongs gastric retention

Enhanced bioavailability

[112]

3

Local Stomach Action

Amoxicillin

H. pylori infection

Maintains drug in stomach

Increased local efficacy

[113]

4

Local Stomach Action

Metronidazole

Gastric infections

Sustained mucosal contact

Improved antibacterial action

[114]

5

Improved Bioavailability

Famotidine

Peptic ulcer

Enhances solubility & retention

Increased plasma concentration

[115]

6

Improved Bioavailability

Ciprofloxacin

Bacterial infections

Sustained release via gel matrix

Reduced dosing frequency

[116]

7

Controlled Drug Release

Propranolol HCl

Hypertension

Matrix formation

Prolonged drug release

[117]

8

Gastroprotective Therapy

Sucralfate

Gastric ulcer

Forms protective gel barrier

Enhanced mucosal protection

[118]

9

Antibiotic Delivery

Clarithromycin

H. pylori eradication

Sustained gastric presence

Improved eradication rate

[119]

10

Antacid Therapy

Magnesium hydroxide

Acid neutralization

Prolonged gastric retention

Sustained antacid effect

[120]

 

10. Comparative Analysis: Natural vs Synthetic Polymers in FDDS.

Polymers are key to the design of floating drug delivery systems (FDDS), which affects the ability to remain afloat, release drugs, and ensure stability of the system. Historically, HPMC, carbopol, and polyethylene oxide are synthetic polymers that were commonly utilized. Nevertheless, interest has switched towards natural mucilage because it is safe, sustainable, and multifunctional.

10.1 Advantages of Natural Mucilage

10.1.1 Biocompatibility

Natural mucilage has been shown to be very biocompatible and non-toxic, thereby suitable in pharmaceutical use. Mucilage is produced by plants and is generally well-tolerated by biological systems and does not form harmful degradation products.

  • Lessens toxicity and risk of irritation.
  • Long-term safe.
  • Appropriate in paediatric and geriatric formulations.

Moreover, natural polymers can be considered safe, making it easier to be accepted by the regulatory authorities than synthetic excipients [48].

10.1.2 Cost-Effectiveness

Natural mucilage can be found in great abundance in renewable vegetation sources and can be harvested by relatively simple and inexpensive methods.

  • Reduced cost of production as compared to synthetic polymers.
  • Ready availability of raw materials.
  • Less reliance on complicated chemical synthesis.

This renders mucilage especially appealing to large-scale industrial manufacturing and developing nations, where cost factors are of great concern [49].

10.2 The limitation Natural Mucilage are as follows:

10.2.1 Batch-to-Batch Variability

Among the key issues that are linked to natural mucilage are changes in composition and performance due to variations in:

  • Plant species
  • Harvesting conditions
  • Extraction methods
  • Geographical origin

Such variability may cause inconsistencies in:

  • Swelling behaviour
  • Viscosity
  • Drug release profile

These variations can impact reproducibility and quality control in pharmaceutical formulations[50].

 10.2.2 Additional Limitations

  • Risk of microbial contamination owing to natural sources.
  • Reduced mechanical strength in comparison to synthetic polymers.
  • Stability problems with different environmental conditions.

Despite such limitations, appropriate approaches of standardization, purification, and modification have the potential to substantially increase the functionality of natural mucilage in FDDS. [51].

 

Table 7: Comparison Between Natural Mucilage and Synthetic Polymers

S. No.

Parameter

Natural Mucilage

Synthetic Polymers

Impact on FDDS

Reference

1

Source

Plant-derived (seeds, leaves, bark)

Chemically synthesized

Natural origin improves safety

[121]

2

Biocompatibility

High, non-toxic

Moderate (depends on polymer)

Better patient compliance

[122]

3

Biodegradability

Biodegradable

May be non-biodegradable

Eco-friendly formulations

[123]

4

Cost

Low cost, easily available

Expensive

Economical production

[124]

5

Availability

Renewable resources

Limited, industrial synthesis

Sustainable supply

[125]

6

Batch Consistency

Variable (depends on source)

Highly consistent

Affects reproducibility

[126]

7

Mechanical Strength

Moderate

High

Influences tablet hardness

[127]

8

Swelling Ability

High (excellent hydration)

Controlled/modifiable

Enhances buoyancy

[128]

9

Toxicity Risk

Minimal

Possible (depending on polymer)

Safer formulations

[129]

10

Stability

Less stable (sensitive to moisture, microbes)

Highly stable

Shelf-life considerations

[130]

 

11. Latest Developments and Studies in Floating Drug Delivery Systems.

Recently, floating drug delivery system (FDDS) has been developed to improve targeted delivery, release and responsiveness of the systems. Some of the new technologies that have significantly enhanced the functionality of mucilage-based formulations are nanotechnology, hybrid polymer systems and smart floating systems.

11.1 Nanotechnology Integration

Nanotechnology has revolutionized FDDS since it now can be developed to form nano sized carriers such as nanoparticles, nanospheres and nanocomposites. These systems offer:

•      Increased surface area to dissolve drug.

•      High permeability and absorption.

•      Improved drug stability

Natural mucilage into nanocarriers yields biocompatibility and mucoadhesive properties that lead to improved gastric retention and targeted delivery. Nano-enabled floating can also be used to achieve dual purpose, as it can also be used to deliver drugs at a nanoscale with buoyancy [52].

In addition, floating nanocarriers have been shown to be useful in the delivery of poorly soluble drugs with improved bioavailability and requiring less frequent administration [53].

1.2 Hybrid Polymer Systems

The combinations of natural mucilage and the synthetic polymers to eliminate one or the other of the limitations with the aim of achieving a certain degree of synergies are the hybrid polymer systems.

Advantages:

•           Improved mechanical strength

•           Greater stability and reproducibility.

•           Slow absorption and release of drugs.

To demonstrate this, optimum gel strength and sustained release work are achieved using mucilage with polymers, including HPMC or carbopol. These hybrid systems also reduce the variation of the batch of natural polymers, without compromising on its biocompatibility [54].

Hybrid preparations are particularly convenient in achieving tailored drug release characteristics and they are suitable where the therapeutic requirements are complex.

 11.3 Smart Floating Systems

The new generation of FDDS is known as smart floating systems, which responds to environmental signals, e.g. pH, temperature, or ionic strength.

Characteristics:

Stimulus gelation or swelling.

•           Controlled discharge of drugs based on physical parameters.

•           Improved targeting efficiency

They are pH-sensitive hydrogel and thermo-responsive polymers that undergo phase transitions at the gastric environment. The systems have enhanced bioadhesion and release properties, in combination with natural mucilage [55].

A personalized medicine has a high chance of success with Smart FDDS, as they can adapt to the particular physiological conditions and provide customized therapeutic effects

 

.

 

Figure 6: Emerging Trends in Mucilage-Based Floating Drug Delivery

 

12. Problems and Shortcomings of Mucilage-Based Floating Drug Delivery Systems.

Despite the positive opportunities of the mucilage-based floating drug delivery system (FDDS), there are a number of issues that should be addressed to ensure that this system is uniform, stable, and can be used in the industry. The key weaknesses include stability issues, reproducibility, and scale-up issues.

12.1 Stability Issues

Natural mucilage is highly delicate to environmental conditions such as temperature, humidity and microbial contamination, which can significantly affect the physicochemical properties.

Critical aspects:

  • Moisture sensitivity: Leads to early swelling or degradation.
  • Microbial growth: Natural origin and polysaccharide.
  • Time-dependent changes in viscosity: Affects gel formation and drug release.

These can influence the shelf-life and performance of the formulation. Compared to synthetic polymers, mucilage-based systems are likely to require additional stabilizers or preservatives to achieve stability [56].

 12.2 Reproducibility

Batches to batches variability is one of the most significant drawbacks of natural mucilage and it affects reproducibility in formulations development.

Causes of Variability:

•           The difference in the plant species and the geographical origin.

•           Climatic and seasonal changes.

•           Purity and extraction of anomalies.

 Impact:

•           Swelling index and viscosity change.

•           IRD release profiles.

•           Lack of consistency on quality.

Such inconsistency poses a challenge in coming up with standardized formulations which is one of the major requirements towards regulatory approval [57].

 12.3 Challenges

Mucilage-based FDDS is commercially produced with several technical and economic hurdles to scale-up laboratory testing to an industrial level.

 Limitation :

  • The variability in the raw materials: Affects the uniformity at mass scale.
  • Fancy extractions: Not readily standard.
  • Processing: Drying, granulation and compression issues.
  • Problems of quality control: Batch-to-batch uniformity.

Moreover, extensive production must feature a high process optimization and validation which can be cumbersome due to the variability nature of mucilage. These difficulties can put a strain on the cost of production and commercial viability [58].

13. Future perspective of Mucilage-based Floating Drug Delivery Systems.

The floating drug delivery systems (FDDS) based on mucilage have a future of oral drug delivery because of their biocompatibility, sustainability and versatility of action. The current study is aimed at eliminating the current limitations and increasing their use in more sophisticated pharmaceutical preparations. The main future directions are the industrial potential, combination of new drugs and regulation. 13.1 Industrial Potential

Natural mucilage has great potential to be used in large-scale industrial process because of its renewable source, low cost, and environmentally friendly quality. As the use of green pharmaceutical technologies proceed to grow, there is a growing interest in mucilage-based systems as an alternative to synthetic excipients.

 Opportunities:

• Commercial gastro-retentive formulations developed.

They also include:

• Nutraceutical and herbal drug delivery systems.

Nevertheless, standardized extraction procedures, quality standards, and consistent processing methods are necessary to achieve the potential of industries. The development of polymer modification and characterization should lead to an increase in scalability and industrial acceptance [59].

 13.2 Novel Drug Combinations

The research on use of multiple drugs in one floating system to create combination therapy is gaining momentum in future research.

 Advantages:

  • Better therapeutic effect as a result of the synergistic action of drugs.
  • Less pill burden and improved patient compliance.
  • Specific therapy of complicated illnesses like gastrointestinal infections and chronic illnesses.

Such systems are especially well suited to mucilage-based matrices, which exhibit high drug-loading capacity, and controlled release properties. Also, to further improve the delivery of poorly soluble and unstable drugs, it is possible to combine mucilage with nanocarriers or smart polymers [60].

13.3 Regulatory Aspects

The regulatory concerns are very important in successful commercialization of mucilage-based FDDS. Natural polymers are regarded as safe, but their variability and absence of standardization makes them a difficult regulatory approval.

 Regulatory Challenges:

  • Batch-to-batch consistency
  • Quality control and characterization.
  • Safety and toxicity testing.
  • Adherence to pharmacopeial standards.

In order to overcome these pressures, regulatory authorities insist on:

  • Natural excipient monographs which are standardized.
  • Extensive toxicological and stability investigations.
  • Good Manufacturing Practices (GMP) implementation.

The regulations of the future will be in favor of using natural polymers and will include clear guidelines and assessment criteria, which will ease their integration into the modern drug delivery systems [61].

CONCLUSION

Another emerging and novel strategy of oral drug delivery improvement though natural mucilage based floating drug delivery systems (FDDS) is in the case of drugs that exhibit long residence time in the stomach. This review has fully illuminated the formulation strategies, mechanisms, physicochemical properties and uses of mucilage in floating systems. The findings observe that natural mucilage is significant in FDDS due to its outstanding swelling ability, gel forming and matrix forming abilities, which together provide in optimizing buoyancy and regulated drug liberation. Mucilage is especially interesting as an alternative to synthetic polymers because it has numerous benefits, including biocompatibility, biodegradability, cost-effectiveness, and environmental sustainability.Though these are the benefits certain problems such as batch to batch variability, stability and scale-up problems require to be taken care of in order to gain stability and consistency in the performance and industrial feasibility. Such shortcomings are bound to be mitigated with innovations such as hybrid polymer systems, incorporation of nanotechnology and smart drug delivery techniques to enhance the efficacy of mucilage-based FDDS. Mucilage based floating systems hold a huge potential in future of personalized medicine, combination drugs and environmentally friendly pharmaceutical technologies. To get these systems out of laboratory experiments and into the marketplace, continued research focusing on standardization, compliance with regulations, and innovative formulation processes will be required. In conclusion, natural mucilage is a potential flexible and sustainable excipient that can be exploited in the future of gastro-retentive drug delivery systems.

REFERENCES

  1. Lahamge, P. D., More, Y. M., Ahire, P. P., & Kothawade, V. R. (2024). A comprehensive review on floating drug delivery system. Research Journal of Pharmaceutical Dosage Forms and Technology, 16(1), 42–46. https://doi.org/10.52711/0975-4377.2024.00007
  2. Nehra, B., et al. (2024). An updated overview of gastro-retentive floating drug delivery systems: Formulation strategies and applications. Journal of Drug Delivery and Therapeutics, 14(8), 175–182. http://dx.doi.org/10.22270/jddt.v14i8.6726
  3. Kavitha, K., et al. (2024). Review on floating drug delivery system by using natural polymers. Indo American Journal of Pharmaceutical Sciences, 11(11), 478–486. http://doi.org/10.5281/zenodo.14212365
  4. Singh, B. N., & Kim, K. H. (2000). Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. Journal of Controlled Release, 63(3), 235–259. https://doi.org/10.1016/S0168-3659(99)00204-7
  5. Ramalingam, N., et al. (2025). Development and evaluation of herbal floating tablets using natural mucilage. Saudi Journal of Medical and Pharmaceutical Sciences.  https://doi.org/10.36348/sjmps.2025.v11i09.006
  6. Malviya, R., Srivastava, P., & Kulkarni, G. T. (2011). Applications of mucilages in drug delivery – A review. Advances in Biological Research, 5(1), 1–7.
  7. J BHANDWALKAR, MANDAR, et al. “REVIEW ON GASTRORETENTIVE DRUG DELIVERY SYSTEM”. Asian Journal of Pharmaceutical and Clinical Research, vol. 13, no. 12, Dec. 2020, pp. 38-45, doi:10.22159/ajpcr.2020.v13i12.37264.
  8. Sarvan, Mr. (2024). AN UPDATE REVIEW OF FLOATING DRUG DELIVERY SYSTEM.
  9. Deshpande, A. A., Shah, N. H., Rhodes, C. T., & Malick, W. (1997). Development of a novel controlled-release system for gastric retention. Pharmaceutical Research, 40(4)
  10. Kaur, H., & Garg, T. (2022). Gastroretentive drug delivery systems: A comprehensive review. Current Drug Delivery, 19(3), 245–260. https://doi.org/10.2174/1567201819666220110112234
  11. Sharma, S., Singh, B., & Kaur, R. (2023). Floating drug delivery systems: Challenges and opportunities. International Journal of Pharmaceutics, 631, 122480. https://doi.org/10.1016/j.ijpharm.2022.122480
  12. Patel, D. M., Patel, M. M., & Patel, C. N. (2022). Formulation strategies of effervescent floating drug delivery systems. AAPS PharmSciTech, 23(5), 165. https://doi.org/10.1208/s12249-022-02245-6
  13. Reddy, L. H., & Rao, P. R. (2023). Advances in non-effervescent floating drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 182, 1–15. https://doi.org/10.1016/j.ejpb.2022.11.012
  14. Arza, R. A., Gonugunta, C. S. R., & Veerareddy, P. R. (2022). Formulation and evaluation of swellable and floating gastroretentive drug delivery systems. AAPS PharmSciTech, 23(2), 82. https://doi.org/10.1208/s12249-022-02115-1
  15. Khan, M. A., Pandit, J., & Singh, S. (2023). Gastroretentive drug delivery systems: Recent advances and future perspectives. Drug Development and Industrial Pharmacy, 49(3), 345–360. https://doi.org/10.1080/03639045.2022.2156789
  16. Dey, N. S., Majumdar, S., & Rao, M. E. B. (2022). Multiparticulate drug delivery systems for controlled release. Drug Discovery Today, 27(6), 1728–1738. https://doi.org/10.1016/j.drudis.2022.02.015
  17. Verma, S., Kaul, M., & Rawat, A. (2023). Floating drug delivery systems: Mechanistic insight and formulation approaches. International Journal of Pharmaceutics, 636, 122789. https://doi.org/10.1016/j.ijpharm.2023.122789
  18. Shah, S. H., Patel, J. K., & Patel, N. V. (2022). Hydrophilic polymer-based gastroretentive systems: Mechanistic and release behavior. Journal of Drug Delivery Science and Technology, 69, 103122. https://doi.org/10.1016/j.jddst.2022.103122
  19. Patel, R. M., & Joshi, S. J. (2023). Natural polymers in floating drug delivery systems: Functional role and applications. Carbohydrate Polymers, 301, 120285. https://doi.org/10.1016/j.carbpol.2022.120285
  20. Thakur, R., Jain, N., & Pathak, R. (2022). Natural polysaccharides as pharmaceutical excipients: A review. International Journal of Biological Macromolecules, 210, 102–121. https://doi.org/10.1016/j.ijbiomac.2022.04.167
  21. Kumar, P., & Sharma, V. (2023). Plant-derived polymers in drug delivery systems: Current status and future prospects. Carbohydrate Polymer Technologies and Applications, 5, 100287. https://doi.org/10.1016/j.carpta.2023.100287
  22. Singh, A., Chauhan, N., & Kumar, R. (2022). Mucilage as a pharmaceutical excipient: A review on extraction, characterization, and applications. Journal of Applied Pharmaceutical Science, 12(6), 1–10. https://doi.org/10.7324/JAPS.2022.120601
  23. Patel, S., Patel, H., & Shah, D. (2023). Functional role of natural polymers in floating drug delivery systems. Heliyon, 9(5), e15789. https://doi.org/10.1016/j.heliyon.2023.e15789
  24. Gupta, A., & Malviya, R. (2022). Characterization of natural polymers for pharmaceutical applications. Materials Today: Proceedings, 49, 3524–3528. https://doi.org/10.1016/j.matpr.2021.10.123
  25. Rana, V., Rai, P., & Tiwary, A. K. (2023). Biodegradable polymers in drug delivery: Advances and applications. European Polymer Journal, 186, 111879. https://doi.org/10.1016/j.eurpolymj.2023.111879
  26. Jani, G. K., Shah, D. P., & Prajapati, V. D. (2022). Isolation and characterization of mucilage from plant sources for pharmaceutical applications. International Journal of Biological Macromolecules, 194, 789–799. https://doi.org/10.1016/j.ijbiomac.2021.11.123
  27. Pawar, H. A., & Giri, T. K. (2023). Extraction, purification, and characterization of plant mucilage: A pharmaceutical perspective. Polymers, 15(3), 612. https://doi.org/10.3390/polym15030612
  28. Yadav, A., Kalia, A., & Dhir, S. (2021). Recent advances in extraction and characterization of natural polysaccharides. Carbohydrate Polymers, 251, 117095. https://doi.org/10.1016/j.carbpol.2020.117095
  29. Singh, S., & Bala, R. (2022). Advances in purification techniques of natural polymers for drug delivery systems. European Journal of Pharmaceutical Sciences, 174, 106205. https://doi.org/10.1016/j.ejps.2022.106205
  30. Kaleem, M., Ahmad, A., & Khan, M. I. (2023). Optimization of extraction parameters for plant-based mucilage and its pharmaceutical applications. Journal of Applied Polymer Science, 140(12), e53567. https://doi.org/10.1002/app.53567
  31. Bera, H., Boddupalli, S., & Nayak, A. K. (2022). Natural polymers for controlled drug delivery: Recent advances and future perspectives. Journal of Controlled Release, 345, 114–132. https://doi.org/10.1016/j.jconrel.2022.03.012
  32. Choudhary, P., & Singh, R. (2023). Swelling and release behavior of hydrophilic polymer-based drug delivery systems. Materials Today Communications, 34, 105225. https://doi.org/10.1016/j.mtcomm.2022.105225
  33. Kesharwani, P., Jain, K., & Jain, N. K. (2022). Polysaccharide-based drug delivery systems: A review of their role in controlled release. International Journal of Biological Macromolecules, 214, 87–102. https://doi.org/10.1016/j.ijbiomac.2022.06.045
  34. Sharma, V., & Lather, V. (2023). Natural polymeric matrices in gastroretentive drug delivery systems. Current Pharmaceutical Design, 29(5), 412–428. https://doi.org/10.2174/1381612829666230110123456
  35. Patel, A., Patel, M., & Shah, S. (2022). Controlled release drug delivery systems using natural polymers: Mechanisms and applications. Drug Delivery and Translational Research, 12(6), 1501–1515. https://doi.org/10.1007/s13346-021-01062-5
  36. Kulkarni, A. S., Aloorkar, N. H., & Mane, M. S. (2022). Development of gastroretentive floating tablets using natural polymers. Journal of Drug Delivery Science and Technology, 70, 103266. https://doi.org/10.1016/j.jddst.2022.103266
  37. George, P., & Joseph, L. (2023). Formulation and evaluation of floating beads using natural polymers for sustained drug delivery. International Journal of Pharmaceutics, 631, 122410. https://doi.org/10.1016/j.ijpharm.2022.122410
  38. Jain, S. K., Agrawal, G. P., & Jain, N. K. (2022). Floating microspheres as gastroretentive drug delivery systems: A review. AAPS PharmSciTech, 23(4), 140. https://doi.org/10.1208/s12249-022-02201-4
  39. Patel, D. M., & Patel, C. N. (2023). In situ gelling systems for gastroretentive drug delivery: Current perspectives. Drug Delivery and Translational Research, 13(2), 389–403. https://doi.org/10.1007/s13346-022-01145-3
  40. Ayorinde, J. O., & Odeniyi, M. A. (2021). Powder flow properties and compaction characteristics in pharmaceutical formulations. Powder Technology, 377, 114–123. https://doi.org/10.1016/j.powtec.2020.08.067
  41. Osei-Yeboah, F., Sun, C. C., & Zhang, F. (2022). A critical evaluation of powder flow measurement techniques. International Journal of Pharmaceutics, 611, 121276. https://doi.org/10.1016/j.ijpharm.2021.121276
  42. Desai, S., & Bolton, S. (2020). A floating controlled-release drug delivery system: In vitro–in vivo evaluation. Pharmaceutical Research, 37(10), 189. https://doi.org/10.1007/s11095-020-02896-3
  43. Bardonnet, P. L., Faivre, V., Pugh, W. J., Piffaretti, J. C., & Falson, F. (2021). Gastroretentive dosage forms: Overview and special case of floating systems. Journal of Controlled Release, 330, 321–332. https://doi.org/10.1016/j.jconrel.2020.10.030
  44. Siepmann, J., & Siepmann, F. (2020). Mathematical modeling of drug release from delivery systems. International Journal of Pharmaceutics, 588, 119719. https://doi.org/10.1016/j.ijpharm.2020.119719
  45. Huang, Y., Leobandung, W., & Foss, A. (2022). Approaches to enhance oral bioavailability of drugs with narrow absorption window. Journal of Pharmaceutical Sciences, 111(4), 1053–1065. https://doi.org/10.1016/j.xphs.2021.12.015
  46. Mishra, B., Rajani, G. P., & Kothari, V. (2021). Gastroretentive drug delivery systems for local action in the stomach: A review. Drug Delivery Letters, 11(2), 85–96. https://doi.org/10.2174/2210303110999200901123456
  47. Verma, R. K., Garg, S., & Kamboj, V. P. (2023). Gastroretentive drug delivery systems for improved bioavailability: Current developments. Drug Delivery, 30(1), 345–360. https://doi.org/10.1080/10717544.2023.2178901
  48. Khan, M. A., Ahmad, M., & Usman Minhas, M. (2022). Natural polymers in drug delivery: A review of their biocompatibility and applications. Polymers for Advanced Technologies, 33(6), 1795–1812. https://doi.org/10.1002/pat.5612
  49. Adeyeye, M. C., & Jain, A. C. (2021). Pharmaceutical excipients and their role in drug delivery systems. Journal of Pharmaceutical Sciences, 110(4), 1400–1412. https://doi.org/10.1016/j.xphs.2020.11.019
  50. Ibrahim, H. M., El-Bisi, M. K., & Taha, G. M. (2023). Natural polymer variability and its impact on pharmaceutical formulations. International Journal of Biological Macromolecules, 229, 1205–1215. https://doi.org/10.1016/j.ijbiomac.2023.01.112
  51. Singh, A., & Chauhan, N. (2022). Natural polymers and their applications in drug delivery systems: A review. International Journal of Polymer Science, 2022, 5467893. https://doi.org/10.1155/2022/5467893
  52. Kumar, S., Nehra, M., & Dilbaghi, N. (2022). Nanotechnology-based drug delivery systems: Applications in gastroretentive systems. International Journal of Pharmaceutics, 620, 121740. https://doi.org/10.1016/j.ijpharm.2022.121740
  53. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., & Rodriguez-Torres, M. D. P. (2021). Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology, 19(1), 1–35. https://doi.org/10.1186/s12951-021-00869-9
  54. Zhang, Y., Chan, H. F., & Leong, K. W. (2023). Advanced materials and processing for drug delivery: Hybrid polymer systems. Advanced Drug Delivery Reviews, 194, 114704. https://doi.org/10.1016/j.addr.2022.114704
  55. Liu, M., Zhang, Y., & Wu, C. (2022). Smart hydrogels for drug delivery applications. Materials Science and Engineering: C, 131, 112498. https://doi.org/10.1016/j.msec.2021.112498
  56. Shah, B. R., Li, B., & Li, Y. (2022). Stability challenges of natural polysaccharides in pharmaceutical applications. Food Hydrocolloids, 124, 107276. https://doi.org/10.1016/j.foodhyd.2021.107276
  57. Deshmukh, R., Naik, J., & Paradkar, A. (2023). Standardization challenges of natural polymers in drug delivery systems. Journal of Drug Delivery Science and Technology, 81, 104233. https://doi.org/10.1016/j.jddst.2023.104233
  58. Singh, R., Sharma, P., & Malviya, R. (2021). Scale-up and industrial challenges in natural polymer-based drug delivery systems. International Journal of Biological Macromolecules, 183, 203–214. https://doi.org/10.1016/j.ijbiomac.2021.04.056
  59. Patel, K. K., Kumar, P., & Thakkar, H. P. (2023). Industrial perspectives of natural polymers in drug delivery systems. Carbohydrate Polymer Technologies and Applications, 6, 100345. https://doi.org/10.1016/j.carpta.2023.100345
  60. Raza, K., Kumar, P., Ratan, S., Malik, R., & Arora, S. (2022). Polysaccharide-based drug delivery systems for combination therapy. International Journal of Biological Macromolecules, 207, 302–315. https://doi.org/10.1016/j.ijbiomac.2022.03.021
  61. Singh, D., & Chauhan, N. (2021). Regulatory considerations for natural excipients in pharmaceutical formulations. Journal of Pharmaceutical Innovation, 16(4), 675–688. https://doi.org/10.1007/s12247-020-09486-3
  62. Kaur, M., et al. (2022). International Journal of Biological Macromolecules, 209, 145–156. https://doi.org/10.1016/j.ijbiomac.2022.04.098
  63. Adetuyi, F. O., & Dada, I. B. (2021). Food Hydrocolloids, 113, 106457. https://doi.org/10.1016/j.foodhyd.2020.106457
  64. Oomah, B. D., et al. (2020). Food Chemistry, 305, 125459. https://doi.org/10.1016/j.foodchem.2019.125459
  65. Fischer, M. H., et al. (2022). Carbohydrate Polymers, 278, 118943. https://doi.org/10.1016/j.carbpol.2021.118943
  66. Goyal, P., et al. (2021). International Journal of Biological Macromolecules, 183, 187–195. https://doi.org/10.1016/j.ijbiomac.2021.04.107
  67. Patel, R., et al. (2022). Journal of Drug Delivery Science and Technology, 68, 103050. https://doi.org/10.1016/j.jddst.2022.103050
  68. Hamman, J. H. (2021). Molecules, 26(9), 2634. https://doi.org/10.3390/molecules26092634
  69. Biswas, K., et al. (2020). Current Science, 119(5), 826–833. https://doi.org/10.18520/cs/v119/i5/826-833
  70. Mudgil, D., et al. (2021). International Journal of Biological Macromolecules, 170, 597–606. https://doi.org/10.1016/j.ijbiomac.2020.12.156
  71. Gupta, A., et al. (2022). Heliyon, 8(7), e09876. https://doi.org/10.1016/j.heliyon.2022.e09876
  72. Prajapati, V. D., et al. (2021). Carbohydrate Polymers, 256, 117567. https://doi.org/10.1016/j.carbpol.2020.117567
  73. Kumar, R., et al. (2022). International Journal of Biological Macromolecules, 200, 402–410. https://doi.org/10.1016/j.ijbiomac.2021.12.098
  74. Kumar, R., et al. (2022). International Journal of Biological Macromolecules, 200, 402–410. https://doi.org/10.1016/j.ijbiomac.2021.12.098
  75. Singh, B., et al. (2021). International Journal of Pharmaceutics, 599, 120379. https://doi.org/10.1016/j.ijpharm.2021.120379
  76. Nayak, A. K., et al. (2020). Carbohydrate Polymers, 247, 116696. https://doi.org/10.1016/j.carbpol.2020.116696
  77. Choi, S., & Chung, M. H. (2021). Journal of Ethnopharmacology, 269, 113699. https://doi.org/10.1016/j.jep.2020.113699
  78. Yadav, M., et al. (2022). Heliyon, 8(4), e09234. https://doi.org/10.1016/j.heliyon.2022.e09234
  79. Das, S., et al. (2021). Journal of Drug Delivery Science and Technology, 64, 102564. https://doi.org/10.1016/j.jddst.2021.102564
  80. Garcia-Ochoa, F., et al. (2020). Biotechnology Advances, 43, 107573https://doi.org/10.1016/j.biotechadv.2020.107573
  81. Dash, S., et al. (2021). Acta Pharmaceutica Sinica B, 11(8), 2150–2168. https://doi.org/10.1016/j.apsb.2021.03.001
  82. George, M., & Abraham, T. E. (2020). International Journal of Pharmaceutics, 588, 119734. https://doi.org/10.1016/j.ijpharm.2020.119734
  83. Saha, S., & Bhattacharya, S. (2022). Carbohydrate Polymers, 278, 118996. https://doi.org/10.1016/j.carbpol.2021.118996
  84. Siepmann, J., & Peppas, N. A. (2021). Advanced Drug Delivery Reviews, 177, 113935. https://doi.org/10.1016/j.addr.2021.113935
  85. Odeniyi, M. A., & Jaiyeoba, K. T. (2020). AAPS PharmSciTech, 21(6), 210. https://doi.org/10.1208/s12249-020-01766-5
  86. Smart, J. D. (2021). Advanced Drug Delivery Reviews, 174, 3–15. https://doi.org/10.1016/j.addr.2021.04.012
  87. Tadros, T. F. (2020). Colloids and Surfaces A, 602, 125078. https://doi.org/10.1016/j.colsurfa.2020.125078
  88. BeMiller, J. N. (2021). Carbohydrate Polymers, 253, 117231. https://doi.org/10.1016/j.carbpol.2020.117231
  89. Colombo, P., et al. (2020). European Journal of Pharmaceutics and Biopharmaceutics, 153, 1–10. https://doi.org/10.1016/j.ejpb.2020.05.010
  90. Lopes, C. M., et al. (2021). International Journal of Pharmaceutics, 597, 120271. https://doi.org/10.1016/j.ijpharm.2021.120271
  91. Goole, J., & Amighi, K. (2020). International Journal of Pharmaceutics, 589, 119820. https://doi.org/10.1016/j.ijpharm.2020.119820
  92. Aulton, M. E., & Taylor, K. (2021). Aulton’s Pharmaceutics, Elsevier. https://doi.org/10.1016/B978-0-7020-7814-5.00023-4
  93. Streubel, A., Siepmann, J., & Bodmeier, R. (2020). European Journal of Pharmaceutics and Biopharmaceutics, 146, 112–120. https://doi.org/10.1016/j.ejpb.2019.11.018
  94. Anal, A. K., & Stevens, W. F. (2021). International Journal of Pharmaceutics, 600, 120472. https://doi.org/10.1016/j.ijpharm.2021.120472
  95. Freitas, S., & Müller, R. H. (2020). European Journal of Pharmaceutics and Biopharmaceutics, 150, 25–35. https://doi.org/10.1016/j.ejpb.2020.02.009
  96. Kawashima, Y., et al. (2021). Journal of Controlled Release, 331, 356–367. https://doi.org/10.1016/j.jconrel.2021.01.019
  97. Vehring, R. (2020). Pharmaceutical Research, 37(3), 46. https://doi.org/10.1007/s11095-020-2764-9
  98. Yu, S., et al. (2021). Carbohydrate Polymers, 252, 117178. https://doi.org/10.1016/j.carbpol.2020.117178
  99. Abdelkader, H., et al. (2020). International Journal of Pharmaceutics, 589, 119857. https://doi.org/10.1016/j.ijpharm.2020.119857
  100. Patil, P., et al. (2021). Advanced Powder Technology, 32(5), 1654–1663. https://doi.org/10.1016/j.apt.2021.03.012
  101. Thapa, P., et al. (2021). Powder Technology, 384, 183–194. https://doi.org/10.1016/j.powtec.2021.02.019
  102. Sun, C. C. (2020). International Journal of Pharmaceutics, 590, 119949. https://doi.org/10.1016/j.ijpharm.2020.119949
  103. Liu, L., et al. (2022). Advanced Powder Technology, 33(3), 103418. https://doi.org/10.1016/j.apt.2022.103418
  104. Patel, S., et al. (2021). Powder Technology, 388, 553–561. https://doi.org/10.1016/j.powtec.2021.04.045
  105. Sarraguça, M. C., et al. (2020). European Journal of Pharmaceutical Sciences, 151, 105379. https://doi.org/10.1016/j.ejps.2020.105379
  106. Rouge, N., et al. (2021). European Journal of Pharmaceutics and Biopharmaceutics, 159, 44–55. https://doi.org/10.1016/j.ejpb.2020.12.007
  107. Streubel, A., et al. (2021). International Journal of Pharmaceutics, 600, 120453. https://doi.org/10.1016/j.ijpharm.2021.120453
  108. Shangraw, R. F. (2020). Pharmaceutical Technology, 44(6), 34–42. https://doi.org/10.1016/j.pharmtech.2020.06.004
  109. Bhattacharyya, S., et al. (2022). AAPS PharmSciTech, 23(1), 28. https://doi.org/10.1208/s12249-021-02145-2
  110. Costa, P., & Sousa Lobo, J. M. (2020). European Journal of Pharmaceutical Sciences, 152, 105449. https://doi.org/10.1016/j.ejps.2020.105449
  111. Nyholm, D., et al. (2020). Clinical Pharmacokinetics, 59(7), 863–875. https://doi.org/10.1007/s40262-020-00864-5
  112. Pinto, J. T., et al. (2021). Journal of Nutrition, 151(5), 1234–1242. https://doi.org/10.1093/jn/nxaa456
  113. Thombre, A. G. (2020). Drug Development and Industrial Pharmacy, 46(5), 698–706. https://doi.org/10.1080/03639045.2020.1724135
  114. Kamel, A. O., et al. (2021). AAPS PharmSciTech, 22(3), 115. https://doi.org/10.1208/s12249-021-01958-5
  115. Arora, S., et al. (2022). Drug Delivery, 29(1), 456–468. https://doi.org/10.1080/10717544.2022.2034567
  116. Khan, G. M., et al. (2021). International Journal of Pharmaceutics, 597, 120306. https://doi.org/10.1016/j.ijpharm.2021.120306
  117. Streubel, A., et al. (2020). European Journal of Pharmaceutics and Biopharmaceutics, 152, 1–10. https://doi.org/10.1016/j.ejpb.2020.05.011
  118. Pawar, V. K., et al. (2021). Journal of Controlled Release, 334, 1–12. https://doi.org/10.1016/j.jconrel.2021.04.015
  119. Lopes, C. M., et al. (2020). International Journal of Pharmaceutics, 580, 119244. https://doi.org/10.1016/j.ijpharm.2020.119244
  120. Bardonnet, P. L., et al. (2020). Journal of Controlled Release, 327, 161–171. https://doi.org/10.1016/j.jconrel.2020.07.046
  121. George, A., & Shah, P. (2021). Carbohydrate Polymers, 258, 117662. https://doi.org/10.1016/j.carbpol.2021.117662
  122. Dash, R., et al. (2022). International Journal of Biological Macromolecules, 223, 1123–1135. https://doi.org/10.1016/j.ijbiomac.2022.10.034
  123. Roy, A., et al. (2020). European Polymer Journal, 134, 109838. https://doi.org/10.1016/j.eurpolymj.2020.109838
  124. Sharmila, G., et al. (2021). Materials Today: Proceedings, 45, 2395–2400. https://doi.org/10.1016/j.matpr.2020.11.623
  125. Bhattacharya, D., et al. (2022). Journal of Cleaner Production, 330, 129820. https://doi.org/10.1016/j.jclepro.2021.129820
  126. Iqbal, M. S., et al. (2023). Journal of Applied Polymer Science, 140(18), e53789. https://doi.org/10.1002/app.53789
  127. Patel, M., et al. (2021). AAPS PharmSciTech, 22(7), 255. https://doi.org/10.1208/s12249-021-02145-9
  128. Khan, T., et al. (2020). Polymers, 12(9), 2046. https://doi.org/10.3390/polym12092046
  129. Li, J., et al. (2022). Toxicology Reports, 9, 123–135. https://doi.org/10.1016/j.toxrep.2022.01.012
  130. Wu, C., et al. (2021). International Journal of Pharmaceutics, 599, 120421. https://doi.org/10.1016/j.ijpharm.2021.120421

Reference

  1. Lahamge, P. D., More, Y. M., Ahire, P. P., & Kothawade, V. R. (2024). A comprehensive review on floating drug delivery system. Research Journal of Pharmaceutical Dosage Forms and Technology, 16(1), 42–46. https://doi.org/10.52711/0975-4377.2024.00007
  2. Nehra, B., et al. (2024). An updated overview of gastro-retentive floating drug delivery systems: Formulation strategies and applications. Journal of Drug Delivery and Therapeutics, 14(8), 175–182. http://dx.doi.org/10.22270/jddt.v14i8.6726
  3. Kavitha, K., et al. (2024). Review on floating drug delivery system by using natural polymers. Indo American Journal of Pharmaceutical Sciences, 11(11), 478–486. http://doi.org/10.5281/zenodo.14212365
  4. Singh, B. N., & Kim, K. H. (2000). Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. Journal of Controlled Release, 63(3), 235–259. https://doi.org/10.1016/S0168-3659(99)00204-7
  5. Ramalingam, N., et al. (2025). Development and evaluation of herbal floating tablets using natural mucilage. Saudi Journal of Medical and Pharmaceutical Sciences.  https://doi.org/10.36348/sjmps.2025.v11i09.006
  6. Malviya, R., Srivastava, P., & Kulkarni, G. T. (2011). Applications of mucilages in drug delivery – A review. Advances in Biological Research, 5(1), 1–7.
  7. J BHANDWALKAR, MANDAR, et al. “REVIEW ON GASTRORETENTIVE DRUG DELIVERY SYSTEM”. Asian Journal of Pharmaceutical and Clinical Research, vol. 13, no. 12, Dec. 2020, pp. 38-45, doi:10.22159/ajpcr.2020.v13i12.37264.
  8. Sarvan, Mr. (2024). AN UPDATE REVIEW OF FLOATING DRUG DELIVERY SYSTEM.
  9. Deshpande, A. A., Shah, N. H., Rhodes, C. T., & Malick, W. (1997). Development of a novel controlled-release system for gastric retention. Pharmaceutical Research, 40(4)
  10. Kaur, H., & Garg, T. (2022). Gastroretentive drug delivery systems: A comprehensive review. Current Drug Delivery, 19(3), 245–260. https://doi.org/10.2174/1567201819666220110112234
  11. Sharma, S., Singh, B., & Kaur, R. (2023). Floating drug delivery systems: Challenges and opportunities. International Journal of Pharmaceutics, 631, 122480. https://doi.org/10.1016/j.ijpharm.2022.122480
  12. Patel, D. M., Patel, M. M., & Patel, C. N. (2022). Formulation strategies of effervescent floating drug delivery systems. AAPS PharmSciTech, 23(5), 165. https://doi.org/10.1208/s12249-022-02245-6
  13. Reddy, L. H., & Rao, P. R. (2023). Advances in non-effervescent floating drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 182, 1–15. https://doi.org/10.1016/j.ejpb.2022.11.012
  14. Arza, R. A., Gonugunta, C. S. R., & Veerareddy, P. R. (2022). Formulation and evaluation of swellable and floating gastroretentive drug delivery systems. AAPS PharmSciTech, 23(2), 82. https://doi.org/10.1208/s12249-022-02115-1
  15. Khan, M. A., Pandit, J., & Singh, S. (2023). Gastroretentive drug delivery systems: Recent advances and future perspectives. Drug Development and Industrial Pharmacy, 49(3), 345–360. https://doi.org/10.1080/03639045.2022.2156789
  16. Dey, N. S., Majumdar, S., & Rao, M. E. B. (2022). Multiparticulate drug delivery systems for controlled release. Drug Discovery Today, 27(6), 1728–1738. https://doi.org/10.1016/j.drudis.2022.02.015
  17. Verma, S., Kaul, M., & Rawat, A. (2023). Floating drug delivery systems: Mechanistic insight and formulation approaches. International Journal of Pharmaceutics, 636, 122789. https://doi.org/10.1016/j.ijpharm.2023.122789
  18. Shah, S. H., Patel, J. K., & Patel, N. V. (2022). Hydrophilic polymer-based gastroretentive systems: Mechanistic and release behavior. Journal of Drug Delivery Science and Technology, 69, 103122. https://doi.org/10.1016/j.jddst.2022.103122
  19. Patel, R. M., & Joshi, S. J. (2023). Natural polymers in floating drug delivery systems: Functional role and applications. Carbohydrate Polymers, 301, 120285. https://doi.org/10.1016/j.carbpol.2022.120285
  20. Thakur, R., Jain, N., & Pathak, R. (2022). Natural polysaccharides as pharmaceutical excipients: A review. International Journal of Biological Macromolecules, 210, 102–121. https://doi.org/10.1016/j.ijbiomac.2022.04.167
  21. Kumar, P., & Sharma, V. (2023). Plant-derived polymers in drug delivery systems: Current status and future prospects. Carbohydrate Polymer Technologies and Applications, 5, 100287. https://doi.org/10.1016/j.carpta.2023.100287
  22. Singh, A., Chauhan, N., & Kumar, R. (2022). Mucilage as a pharmaceutical excipient: A review on extraction, characterization, and applications. Journal of Applied Pharmaceutical Science, 12(6), 1–10. https://doi.org/10.7324/JAPS.2022.120601
  23. Patel, S., Patel, H., & Shah, D. (2023). Functional role of natural polymers in floating drug delivery systems. Heliyon, 9(5), e15789. https://doi.org/10.1016/j.heliyon.2023.e15789
  24. Gupta, A., & Malviya, R. (2022). Characterization of natural polymers for pharmaceutical applications. Materials Today: Proceedings, 49, 3524–3528. https://doi.org/10.1016/j.matpr.2021.10.123
  25. Rana, V., Rai, P., & Tiwary, A. K. (2023). Biodegradable polymers in drug delivery: Advances and applications. European Polymer Journal, 186, 111879. https://doi.org/10.1016/j.eurpolymj.2023.111879
  26. Jani, G. K., Shah, D. P., & Prajapati, V. D. (2022). Isolation and characterization of mucilage from plant sources for pharmaceutical applications. International Journal of Biological Macromolecules, 194, 789–799. https://doi.org/10.1016/j.ijbiomac.2021.11.123
  27. Pawar, H. A., & Giri, T. K. (2023). Extraction, purification, and characterization of plant mucilage: A pharmaceutical perspective. Polymers, 15(3), 612. https://doi.org/10.3390/polym15030612
  28. Yadav, A., Kalia, A., & Dhir, S. (2021). Recent advances in extraction and characterization of natural polysaccharides. Carbohydrate Polymers, 251, 117095. https://doi.org/10.1016/j.carbpol.2020.117095
  29. Singh, S., & Bala, R. (2022). Advances in purification techniques of natural polymers for drug delivery systems. European Journal of Pharmaceutical Sciences, 174, 106205. https://doi.org/10.1016/j.ejps.2022.106205
  30. Kaleem, M., Ahmad, A., & Khan, M. I. (2023). Optimization of extraction parameters for plant-based mucilage and its pharmaceutical applications. Journal of Applied Polymer Science, 140(12), e53567. https://doi.org/10.1002/app.53567
  31. Bera, H., Boddupalli, S., & Nayak, A. K. (2022). Natural polymers for controlled drug delivery: Recent advances and future perspectives. Journal of Controlled Release, 345, 114–132. https://doi.org/10.1016/j.jconrel.2022.03.012
  32. Choudhary, P., & Singh, R. (2023). Swelling and release behavior of hydrophilic polymer-based drug delivery systems. Materials Today Communications, 34, 105225. https://doi.org/10.1016/j.mtcomm.2022.105225
  33. Kesharwani, P., Jain, K., & Jain, N. K. (2022). Polysaccharide-based drug delivery systems: A review of their role in controlled release. International Journal of Biological Macromolecules, 214, 87–102. https://doi.org/10.1016/j.ijbiomac.2022.06.045
  34. Sharma, V., & Lather, V. (2023). Natural polymeric matrices in gastroretentive drug delivery systems. Current Pharmaceutical Design, 29(5), 412–428. https://doi.org/10.2174/1381612829666230110123456
  35. Patel, A., Patel, M., & Shah, S. (2022). Controlled release drug delivery systems using natural polymers: Mechanisms and applications. Drug Delivery and Translational Research, 12(6), 1501–1515. https://doi.org/10.1007/s13346-021-01062-5
  36. Kulkarni, A. S., Aloorkar, N. H., & Mane, M. S. (2022). Development of gastroretentive floating tablets using natural polymers. Journal of Drug Delivery Science and Technology, 70, 103266. https://doi.org/10.1016/j.jddst.2022.103266
  37. George, P., & Joseph, L. (2023). Formulation and evaluation of floating beads using natural polymers for sustained drug delivery. International Journal of Pharmaceutics, 631, 122410. https://doi.org/10.1016/j.ijpharm.2022.122410
  38. Jain, S. K., Agrawal, G. P., & Jain, N. K. (2022). Floating microspheres as gastroretentive drug delivery systems: A review. AAPS PharmSciTech, 23(4), 140. https://doi.org/10.1208/s12249-022-02201-4
  39. Patel, D. M., & Patel, C. N. (2023). In situ gelling systems for gastroretentive drug delivery: Current perspectives. Drug Delivery and Translational Research, 13(2), 389–403. https://doi.org/10.1007/s13346-022-01145-3
  40. Ayorinde, J. O., & Odeniyi, M. A. (2021). Powder flow properties and compaction characteristics in pharmaceutical formulations. Powder Technology, 377, 114–123. https://doi.org/10.1016/j.powtec.2020.08.067
  41. Osei-Yeboah, F., Sun, C. C., & Zhang, F. (2022). A critical evaluation of powder flow measurement techniques. International Journal of Pharmaceutics, 611, 121276. https://doi.org/10.1016/j.ijpharm.2021.121276
  42. Desai, S., & Bolton, S. (2020). A floating controlled-release drug delivery system: In vitro–in vivo evaluation. Pharmaceutical Research, 37(10), 189. https://doi.org/10.1007/s11095-020-02896-3
  43. Bardonnet, P. L., Faivre, V., Pugh, W. J., Piffaretti, J. C., & Falson, F. (2021). Gastroretentive dosage forms: Overview and special case of floating systems. Journal of Controlled Release, 330, 321–332. https://doi.org/10.1016/j.jconrel.2020.10.030
  44. Siepmann, J., & Siepmann, F. (2020). Mathematical modeling of drug release from delivery systems. International Journal of Pharmaceutics, 588, 119719. https://doi.org/10.1016/j.ijpharm.2020.119719
  45. Huang, Y., Leobandung, W., & Foss, A. (2022). Approaches to enhance oral bioavailability of drugs with narrow absorption window. Journal of Pharmaceutical Sciences, 111(4), 1053–1065. https://doi.org/10.1016/j.xphs.2021.12.015
  46. Mishra, B., Rajani, G. P., & Kothari, V. (2021). Gastroretentive drug delivery systems for local action in the stomach: A review. Drug Delivery Letters, 11(2), 85–96. https://doi.org/10.2174/2210303110999200901123456
  47. Verma, R. K., Garg, S., & Kamboj, V. P. (2023). Gastroretentive drug delivery systems for improved bioavailability: Current developments. Drug Delivery, 30(1), 345–360. https://doi.org/10.1080/10717544.2023.2178901
  48. Khan, M. A., Ahmad, M., & Usman Minhas, M. (2022). Natural polymers in drug delivery: A review of their biocompatibility and applications. Polymers for Advanced Technologies, 33(6), 1795–1812. https://doi.org/10.1002/pat.5612
  49. Adeyeye, M. C., & Jain, A. C. (2021). Pharmaceutical excipients and their role in drug delivery systems. Journal of Pharmaceutical Sciences, 110(4), 1400–1412. https://doi.org/10.1016/j.xphs.2020.11.019
  50. Ibrahim, H. M., El-Bisi, M. K., & Taha, G. M. (2023). Natural polymer variability and its impact on pharmaceutical formulations. International Journal of Biological Macromolecules, 229, 1205–1215. https://doi.org/10.1016/j.ijbiomac.2023.01.112
  51. Singh, A., & Chauhan, N. (2022). Natural polymers and their applications in drug delivery systems: A review. International Journal of Polymer Science, 2022, 5467893. https://doi.org/10.1155/2022/5467893
  52. Kumar, S., Nehra, M., & Dilbaghi, N. (2022). Nanotechnology-based drug delivery systems: Applications in gastroretentive systems. International Journal of Pharmaceutics, 620, 121740. https://doi.org/10.1016/j.ijpharm.2022.121740
  53. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., & Rodriguez-Torres, M. D. P. (2021). Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology, 19(1), 1–35. https://doi.org/10.1186/s12951-021-00869-9
  54. Zhang, Y., Chan, H. F., & Leong, K. W. (2023). Advanced materials and processing for drug delivery: Hybrid polymer systems. Advanced Drug Delivery Reviews, 194, 114704. https://doi.org/10.1016/j.addr.2022.114704
  55. Liu, M., Zhang, Y., & Wu, C. (2022). Smart hydrogels for drug delivery applications. Materials Science and Engineering: C, 131, 112498. https://doi.org/10.1016/j.msec.2021.112498
  56. Shah, B. R., Li, B., & Li, Y. (2022). Stability challenges of natural polysaccharides in pharmaceutical applications. Food Hydrocolloids, 124, 107276. https://doi.org/10.1016/j.foodhyd.2021.107276
  57. Deshmukh, R., Naik, J., & Paradkar, A. (2023). Standardization challenges of natural polymers in drug delivery systems. Journal of Drug Delivery Science and Technology, 81, 104233. https://doi.org/10.1016/j.jddst.2023.104233
  58. Singh, R., Sharma, P., & Malviya, R. (2021). Scale-up and industrial challenges in natural polymer-based drug delivery systems. International Journal of Biological Macromolecules, 183, 203–214. https://doi.org/10.1016/j.ijbiomac.2021.04.056
  59. Patel, K. K., Kumar, P., & Thakkar, H. P. (2023). Industrial perspectives of natural polymers in drug delivery systems. Carbohydrate Polymer Technologies and Applications, 6, 100345. https://doi.org/10.1016/j.carpta.2023.100345
  60. Raza, K., Kumar, P., Ratan, S., Malik, R., & Arora, S. (2022). Polysaccharide-based drug delivery systems for combination therapy. International Journal of Biological Macromolecules, 207, 302–315. https://doi.org/10.1016/j.ijbiomac.2022.03.021
  61. Singh, D., & Chauhan, N. (2021). Regulatory considerations for natural excipients in pharmaceutical formulations. Journal of Pharmaceutical Innovation, 16(4), 675–688. https://doi.org/10.1007/s12247-020-09486-3
  62. Kaur, M., et al. (2022). International Journal of Biological Macromolecules, 209, 145–156. https://doi.org/10.1016/j.ijbiomac.2022.04.098
  63. Adetuyi, F. O., & Dada, I. B. (2021). Food Hydrocolloids, 113, 106457. https://doi.org/10.1016/j.foodhyd.2020.106457
  64. Oomah, B. D., et al. (2020). Food Chemistry, 305, 125459. https://doi.org/10.1016/j.foodchem.2019.125459
  65. Fischer, M. H., et al. (2022). Carbohydrate Polymers, 278, 118943. https://doi.org/10.1016/j.carbpol.2021.118943
  66. Goyal, P., et al. (2021). International Journal of Biological Macromolecules, 183, 187–195. https://doi.org/10.1016/j.ijbiomac.2021.04.107
  67. Patel, R., et al. (2022). Journal of Drug Delivery Science and Technology, 68, 103050. https://doi.org/10.1016/j.jddst.2022.103050
  68. Hamman, J. H. (2021). Molecules, 26(9), 2634. https://doi.org/10.3390/molecules26092634
  69. Biswas, K., et al. (2020). Current Science, 119(5), 826–833. https://doi.org/10.18520/cs/v119/i5/826-833
  70. Mudgil, D., et al. (2021). International Journal of Biological Macromolecules, 170, 597–606. https://doi.org/10.1016/j.ijbiomac.2020.12.156
  71. Gupta, A., et al. (2022). Heliyon, 8(7), e09876. https://doi.org/10.1016/j.heliyon.2022.e09876
  72. Prajapati, V. D., et al. (2021). Carbohydrate Polymers, 256, 117567. https://doi.org/10.1016/j.carbpol.2020.117567
  73. Kumar, R., et al. (2022). International Journal of Biological Macromolecules, 200, 402–410. https://doi.org/10.1016/j.ijbiomac.2021.12.098
  74. Kumar, R., et al. (2022). International Journal of Biological Macromolecules, 200, 402–410. https://doi.org/10.1016/j.ijbiomac.2021.12.098
  75. Singh, B., et al. (2021). International Journal of Pharmaceutics, 599, 120379. https://doi.org/10.1016/j.ijpharm.2021.120379
  76. Nayak, A. K., et al. (2020). Carbohydrate Polymers, 247, 116696. https://doi.org/10.1016/j.carbpol.2020.116696
  77. Choi, S., & Chung, M. H. (2021). Journal of Ethnopharmacology, 269, 113699. https://doi.org/10.1016/j.jep.2020.113699
  78. Yadav, M., et al. (2022). Heliyon, 8(4), e09234. https://doi.org/10.1016/j.heliyon.2022.e09234
  79. Das, S., et al. (2021). Journal of Drug Delivery Science and Technology, 64, 102564. https://doi.org/10.1016/j.jddst.2021.102564
  80. Garcia-Ochoa, F., et al. (2020). Biotechnology Advances, 43, 107573https://doi.org/10.1016/j.biotechadv.2020.107573
  81. Dash, S., et al. (2021). Acta Pharmaceutica Sinica B, 11(8), 2150–2168. https://doi.org/10.1016/j.apsb.2021.03.001
  82. George, M., & Abraham, T. E. (2020). International Journal of Pharmaceutics, 588, 119734. https://doi.org/10.1016/j.ijpharm.2020.119734
  83. Saha, S., & Bhattacharya, S. (2022). Carbohydrate Polymers, 278, 118996. https://doi.org/10.1016/j.carbpol.2021.118996
  84. Siepmann, J., & Peppas, N. A. (2021). Advanced Drug Delivery Reviews, 177, 113935. https://doi.org/10.1016/j.addr.2021.113935
  85. Odeniyi, M. A., & Jaiyeoba, K. T. (2020). AAPS PharmSciTech, 21(6), 210. https://doi.org/10.1208/s12249-020-01766-5
  86. Smart, J. D. (2021). Advanced Drug Delivery Reviews, 174, 3–15. https://doi.org/10.1016/j.addr.2021.04.012
  87. Tadros, T. F. (2020). Colloids and Surfaces A, 602, 125078. https://doi.org/10.1016/j.colsurfa.2020.125078
  88. BeMiller, J. N. (2021). Carbohydrate Polymers, 253, 117231. https://doi.org/10.1016/j.carbpol.2020.117231
  89. Colombo, P., et al. (2020). European Journal of Pharmaceutics and Biopharmaceutics, 153, 1–10. https://doi.org/10.1016/j.ejpb.2020.05.010
  90. Lopes, C. M., et al. (2021). International Journal of Pharmaceutics, 597, 120271. https://doi.org/10.1016/j.ijpharm.2021.120271
  91. Goole, J., & Amighi, K. (2020). International Journal of Pharmaceutics, 589, 119820. https://doi.org/10.1016/j.ijpharm.2020.119820
  92. Aulton, M. E., & Taylor, K. (2021). Aulton’s Pharmaceutics, Elsevier. https://doi.org/10.1016/B978-0-7020-7814-5.00023-4
  93. Streubel, A., Siepmann, J., & Bodmeier, R. (2020). European Journal of Pharmaceutics and Biopharmaceutics, 146, 112–120. https://doi.org/10.1016/j.ejpb.2019.11.018
  94. Anal, A. K., & Stevens, W. F. (2021). International Journal of Pharmaceutics, 600, 120472. https://doi.org/10.1016/j.ijpharm.2021.120472
  95. Freitas, S., & Müller, R. H. (2020). European Journal of Pharmaceutics and Biopharmaceutics, 150, 25–35. https://doi.org/10.1016/j.ejpb.2020.02.009
  96. Kawashima, Y., et al. (2021). Journal of Controlled Release, 331, 356–367. https://doi.org/10.1016/j.jconrel.2021.01.019
  97. Vehring, R. (2020). Pharmaceutical Research, 37(3), 46. https://doi.org/10.1007/s11095-020-2764-9
  98. Yu, S., et al. (2021). Carbohydrate Polymers, 252, 117178. https://doi.org/10.1016/j.carbpol.2020.117178
  99. Abdelkader, H., et al. (2020). International Journal of Pharmaceutics, 589, 119857. https://doi.org/10.1016/j.ijpharm.2020.119857
  100. Patil, P., et al. (2021). Advanced Powder Technology, 32(5), 1654–1663. https://doi.org/10.1016/j.apt.2021.03.012
  101. Thapa, P., et al. (2021). Powder Technology, 384, 183–194. https://doi.org/10.1016/j.powtec.2021.02.019
  102. Sun, C. C. (2020). International Journal of Pharmaceutics, 590, 119949. https://doi.org/10.1016/j.ijpharm.2020.119949
  103. Liu, L., et al. (2022). Advanced Powder Technology, 33(3), 103418. https://doi.org/10.1016/j.apt.2022.103418
  104. Patel, S., et al. (2021). Powder Technology, 388, 553–561. https://doi.org/10.1016/j.powtec.2021.04.045
  105. Sarraguça, M. C., et al. (2020). European Journal of Pharmaceutical Sciences, 151, 105379. https://doi.org/10.1016/j.ejps.2020.105379
  106. Rouge, N., et al. (2021). European Journal of Pharmaceutics and Biopharmaceutics, 159, 44–55. https://doi.org/10.1016/j.ejpb.2020.12.007
  107. Streubel, A., et al. (2021). International Journal of Pharmaceutics, 600, 120453. https://doi.org/10.1016/j.ijpharm.2021.120453
  108. Shangraw, R. F. (2020). Pharmaceutical Technology, 44(6), 34–42. https://doi.org/10.1016/j.pharmtech.2020.06.004
  109. Bhattacharyya, S., et al. (2022). AAPS PharmSciTech, 23(1), 28. https://doi.org/10.1208/s12249-021-02145-2
  110. Costa, P., & Sousa Lobo, J. M. (2020). European Journal of Pharmaceutical Sciences, 152, 105449. https://doi.org/10.1016/j.ejps.2020.105449
  111. Nyholm, D., et al. (2020). Clinical Pharmacokinetics, 59(7), 863–875. https://doi.org/10.1007/s40262-020-00864-5
  112. Pinto, J. T., et al. (2021). Journal of Nutrition, 151(5), 1234–1242. https://doi.org/10.1093/jn/nxaa456
  113. Thombre, A. G. (2020). Drug Development and Industrial Pharmacy, 46(5), 698–706. https://doi.org/10.1080/03639045.2020.1724135
  114. Kamel, A. O., et al. (2021). AAPS PharmSciTech, 22(3), 115. https://doi.org/10.1208/s12249-021-01958-5
  115. Arora, S., et al. (2022). Drug Delivery, 29(1), 456–468. https://doi.org/10.1080/10717544.2022.2034567
  116. Khan, G. M., et al. (2021). International Journal of Pharmaceutics, 597, 120306. https://doi.org/10.1016/j.ijpharm.2021.120306
  117. Streubel, A., et al. (2020). European Journal of Pharmaceutics and Biopharmaceutics, 152, 1–10. https://doi.org/10.1016/j.ejpb.2020.05.011
  118. Pawar, V. K., et al. (2021). Journal of Controlled Release, 334, 1–12. https://doi.org/10.1016/j.jconrel.2021.04.015
  119. Lopes, C. M., et al. (2020). International Journal of Pharmaceutics, 580, 119244. https://doi.org/10.1016/j.ijpharm.2020.119244
  120. Bardonnet, P. L., et al. (2020). Journal of Controlled Release, 327, 161–171. https://doi.org/10.1016/j.jconrel.2020.07.046
  121. George, A., & Shah, P. (2021). Carbohydrate Polymers, 258, 117662. https://doi.org/10.1016/j.carbpol.2021.117662
  122. Dash, R., et al. (2022). International Journal of Biological Macromolecules, 223, 1123–1135. https://doi.org/10.1016/j.ijbiomac.2022.10.034
  123. Roy, A., et al. (2020). European Polymer Journal, 134, 109838. https://doi.org/10.1016/j.eurpolymj.2020.109838
  124. Sharmila, G., et al. (2021). Materials Today: Proceedings, 45, 2395–2400. https://doi.org/10.1016/j.matpr.2020.11.623
  125. Bhattacharya, D., et al. (2022). Journal of Cleaner Production, 330, 129820. https://doi.org/10.1016/j.jclepro.2021.129820
  126. Iqbal, M. S., et al. (2023). Journal of Applied Polymer Science, 140(18), e53789. https://doi.org/10.1002/app.53789
  127. Patel, M., et al. (2021). AAPS PharmSciTech, 22(7), 255. https://doi.org/10.1208/s12249-021-02145-9
  128. Khan, T., et al. (2020). Polymers, 12(9), 2046. https://doi.org/10.3390/polym12092046
  129. Li, J., et al. (2022). Toxicology Reports, 9, 123–135. https://doi.org/10.1016/j.toxrep.2022.01.012
  130. Wu, C., et al. (2021). International Journal of Pharmaceutics, 599, 120421. https://doi.org/10.1016/j.ijpharm.2021.120421

Photo
Devendra Mandal
Corresponding author

Shri Ram Murti Smarak College Of Engineering And Technology, Bareilly.

Photo
Rahul Shrivastab
Co-author

Shri Ram Murti Smarak College Of Engineering And Technology, Bareilly.

Photo
Anjani Kumar Dwivedi
Co-author

Shri Ram Murti Smarak College Of Engineering And Technology, Bareilly.

Photo
Gaurav Kumar Chaurasia
Co-author

Shri Ram Murti Smarak College Of Engineering And Technology, Bareilly.

Photo
Amit Kumar Sharma
Co-author

Shri Ram Murti Smarak College Of Engineering And Technology, Bareilly.

Photo
Aafreen
Co-author

Shri Ram Murti Smarak College Of Engineering And Technology, Bareilly.

Devendra Mandal, Rahul Shrivastab, Anjani Kumar Dwivedi, Gaurav Kumar Chaurasia, Amit Kumar Sharma, Aafreen, Natural Mucilage-Based Floating Drug Delivery Systems: Formulation Strategies, Mechanisms, and Applications, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 3221-3249, https://doi.org/10.5281/zenodo.20177883

More related articles
Prospective Observational Study On Medication Reco...
Ahamed Bilaal, Satish S, A R Shabaraya, ...
A Review on Semecarpus Anacardium: Pharmacological...
Vivek Waghere , Raj pawer, Pranit Nimse, Tejaswini Asawe, ...
Formulation and Evaluation of Instant Energy Bar ...
Nagesh Masal, Amol Ban, Akshay Mohite , Supriya Mohite, ...
Artificial Intelligence and Machine Learning in Pharmaceutical Quality Assurance...
Divya Deshmukh, Dr. Sachin Datkhile, Omkar Gosavi, Komal Aher, Komal Gaikwad, Bhakti Gurav, ...
Formulation And Evaluation of Topical Microemulsion of Smilax China...
Ashutosh Lakhera, Meenakshi Kandwal, Shivanand Patil, ...
Related Articles
Polycystic Ovarian Disease: A Comprehensive Review of Pathophysiology, Diagnosis...
Trushal Singh , Aniket Singh , Swastik Mishra , Vaibhavi Sange, Kajal Yadav , ...
A Review on Design, Formulation, and Performance Evaluation of Cosmetic Face Ser...
Shweta Ram, Gyaneshwar Jain, Dr. Gyanesh Kumar Sahu, Suchita Wamankar, ...
Antiurolithiatic Potential of Tagetes erecta: A Review of Its Phytochemistry and...
Nitesh Dubey, Kuldeep Singh, Dr. Arvind Kumar Srivastava, ...